Jacksonville Police Officers and Fire Fighters Health Insurance Trust v. Gilead Sciences, Inc. et al
Case Number:
4:20-cv-06522
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
March 01, 2024
Gilead, Cipla Ink Deal To End HIV Drug Buyers' Antitrust Suit
Gilead Sciences Inc. and generics maker Cipla told a California federal judge Friday they've reached a settlement ending a proposed class action filed by a public employees' health insurance fund over an alleged anti-competitive patent deal to delay the launch of a generic version of the HIV drug Truvada.
-
November 08, 2023
Gilead Wants HIV Drug Antitrust Suit Tossed Again, For Good
Gilead wants a California federal judge to toss a proposed class action alleging the drugmaker paid off generic HIV drug rivals to delay market entry, arguing in a filing made public Tuesday that benefit fund and consumer plaintiffs still haven't addressed "the fundamental issue" that doomed their last complaint.
-
August 29, 2023
Gilead, Generics Co. Beat HIV Drug Antitrust Suit For Now
A California federal judge tossed a proposed class action alleging Gilead paid off generic HIV drugmakers to delay market entry, finding the consumers' claims they were harmed are too speculative, but giving them one final shot at amending their lawsuit.
-
February 10, 2023
HIV Drug Buyers Rip Gilead's Dismissal Bid As 'Nothing New'
A proposed class of consumers slammed Gilead Sciences Inc.'s latest bid to end litigation accusing the biopharmaceutical company of paying off generic HIV drugmakers to delay market entry, telling a California federal judge Friday that Gilead is rehashing old arguments the court previously rejected and that "there's nothing new here."
-
October 21, 2022
HIV Drug Pay-For-Delay Claims Too Speculative, Gilead Says
Gilead Sciences Inc. wants a California federal court to toss a proposed class action accusing the pharmaceutical company of paying off would-be generic competitors to its HIV drugs to delay market entry, arguing the allegations are dependent on too much speculation that such competition would've occurred.